Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 7/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.63 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7817206 | 0.83 | KDM4E (0.88) | CYP1A2CYP2C9CYP2C19KDM4EALDH1A1 | |
| SCHEMBL9401720 | 0.81 | CACNA1B (0.64) | ADORA2BCYP1A2CYP2C9CYP2C19MAPK1 | |
| SCHEMBL3000060 | 0.81 | KDM4E (0.68) | ADORA2BCYP1A2CYP2C9CYP2C19MAPK1 | |
| SCHEMBL27566517 | 0.80 | CACNA1B (0.62) | ADORA2BCYP1A2CYP2C9CYP2C19MAPK1 | |
| SCHEMBL27520045 | 0.80 | CACNA1B (0.65) | ADORA2BCYP1A2CYP2C9CYP2C19MAPK1 | |
| SCHEMBL3032293 | 0.79 | KDM4E (0.80) | CYP1A2CYP2C9CYP2C19KDM4EALDH1A1 | |
| SCHEMBL3027412 | 0.79 | ADORA3 (0.89) | KDM4EALDH1A1SMN1; SMN2TSHRCACNA1B | |
| SCHEMBL5857481 | 0.78 | CACNA1B (1.00) | CACNA1B | |
| SCHEMBL5857475 | 0.78 | CACNA1B (1.00) | CACNA1B | |
| SCHEMBL7368284 | 0.78 | KDM4E (1.00) | CYP1A2CYP2C9CYP2C19KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045428-B2 | Substituted heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2015-06-02 | — | — | US | claimed |
| US-8716319-B2 | Substituted heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2014-05-06 | — | — | US | claimed |
| US-20130324525-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-12-05 | — | — | US | claimed |
| US-9045428-B2 | Substituted heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-8716319-B2 | Substituted heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20130324525-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-12-05 | — | — | US | disclosed |
| US-20100197684-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | GILEAD PALO ALTO, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-20090181986-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | CV THERAPEUTICS, INC. | 2009-07-16 | — | — | US | disclosed |
| US-20090012103-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197684-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | NQO1, GPR119, GLP1R | ADORA2B 713/4885CYP1A2 74/4885CYP2C9 168/4885 |
| US-20130324525-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | NQO1, GPR119, GLP1R | ADORA2B 713/4885CYP1A2 74/4885CYP2C9 168/4885 |
| US-20090181986-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | NQO1, GPR119, GLP1R | ADORA2B 713/4885CYP1A2 74/4885CYP2C9 168/4885 |
| US-20090012103-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | NQO1, GPR119, GLP1R | ADORA2B 713/4885CYP1A2 74/4885CYP2C9 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.